The drug contains the second component of modified Sputnik V and, according to the Gamaleya Center, it will be a supplement that they called the first “line of defense” against COVID-19, so it is in no way a substitute for the vaccine.
Russia, November 27 (RT) .- The new nasal vaccine against the COVID-19 will allow those who come into contact with an infected person not to become carriers of the virus, detailed this Saturday Alexánder Guíntsburg, director of the National Research Center for Epidemiology and Microbiology gamelea who developed the Russian anticovid drug Sputnik V, informa RIA Novosti.
WHAT IS IT AND WHAT ARE THE ADVANTAGES?
According to Guíntsburg, the vaccine represents the second component of Sputnik V modified to be administered nasally.
https://www.youtube.com/watch?v=LhM5T1gASjs
According to the developers, the use of nasal drug it cannot replace a traditional intramuscular vaccine but rather complements it. When applied through the nose, the drug will promote the formation of secretory antibodies that will neutralize the virus, thus creating what they call as “Sterilizing immunity”.
This type of protection will allow the development of the “first line of defense” in the nose and throat, which will prevent a person from becoming a carrier of the infection and transmitting the virus.
“After primary parenteral vaccination we will have systemic immunity; after the additional intranasal vaccination an additional barrier will be created in the form of immunity in the upper respiratory tract ”, explained last Sunday the deputy director for research of the Gamaleya Center, Denís Logunov, quoted by TASS.
THE TRIALS REMAIN UNDERWAY
At the moment, no side effects of the nasal vaccine have been identified, although it should be noted that clinical trials are still continuing.
https://www.youtube.com/watch?v=gdsfwbUm59o
In October, Russian Ministry of Health authorized the use of the drug in volunteers in the framework of the second phase of clinical trials that, according to estimates, will be completed until December 2023 and will have the participation of 500 people. Likewise, it is detailed that the vaccine could be available in international markets in 2022.
Among those who have already tried the vaccine is also the Russian President, Vladimir Putin, who was administered the nasal anticovid drug last Wednesday, a day after he was revaccinated against the coronavirus with the single-dose drug Sputnik Light.
